The Wall Street Journal has a commentary piece from Sidney Taurel, chairman and CEO of Eli Lilly and Company, on a recent flare-up over a drug candidate in clinical trials. The heart-attack drug, prasugrel, was in two trials that were halted pending review of a few cases of adverse effects. Taurel says the media coverage that followed this not only got the story wrong, but resulted in cutting Lilly's market cap by "about $6 billion."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.